JinMatrix Obtains US Patent for Multiplex Molecular Diagnostic Core Technology
[Asia Economy Reporter Moon Hyewon] JinMatrix announced on the 8th that it has obtained a US patent for its proprietary multiplex molecular diagnostic core technology, ‘C-Tag’.
The patented technology is a platform used in the Neoplex multiplex molecular diagnostic product line. The company explained that it is recognized as a next-generation core technology capable of advanced multiplexing, surpassing the previously known limit of up to five simultaneous analyses in conventional real-time PCR technology.
Hot Picks Today
!["SK hynix Is Our Target"... Japanese Firm Bets 7 Trillion Won as Germany Competes for Investment [AIDC Era of Coexistence] ⑪](https://cwcontent.asiae.co.kr/asiaresize/93/2026082117123788782_1787299957.png)
"SK hynix Is Our Target"... Japanese Firm Bets 7 Trillion Won as Germany Competes for Investment [AIDC Era of Coexistence] ⑪
- Was 110 Trillion Won Not Enough? Samsung Electronics Plunges, Dragging Down KOSPI
- All 118 CCTV Footage of Missing Jeju Woman Deleted...Han Donghun: "Police Requested Access Two Months Later"
- "This Trend Is Common in Korea Too"... American Tourist Couple Shocked by Resident's Reprimand, Face Fine for Jogging Shirtless in Venice
- "Monster That Eats Gold" Turns Out to Be Real: Uproar in China as 5-Year-Old Swallows $7,500 Gold Bar, Sparking Questions About Family's Wealth
JinMatrix is currently preparing a comprehensive respiratory virus panel rapid diagnostic product applying the C-Tag core technology to its COVID-19 diagnostic products, which are being exported to Europe, the Middle East, and other regions.
© The Asia Business Daily. All rights reserved. Unauthorized AI training and use prohibited.
